ImmuCell Corporation (NASDAQ:ICCC) Sees Significant Growth in Short Interest

ImmuCell Corporation (NASDAQ:ICCC) was the target of a large growth in short interest in February. As of February 13th, there was short interest totaling 18,071 shares, a growth of 44.1% from the January 29th total of 12,544 shares. Based on an average daily trading volume, of 17,639 shares, the short-interest ratio is presently 1.0 days. Approximately 0.2% of the shares of the stock are sold short. Approximately 0.2% of the shares of the stock are sold short. Based on an average daily trading volume, of 17,639 shares, the short-interest ratio is presently 1.0 days.

ImmuCell Trading Up 0.3%

NASDAQ:ICCC traded up $0.02 on Friday, reaching $6.57. The stock had a trading volume of 3,274 shares, compared to its average volume of 13,386. ImmuCell has a 12-month low of $4.28 and a 12-month high of $7.60. The company has a market cap of $59.46 million, a price-to-earnings ratio of 25.27 and a beta of 0.30. The firm’s fifty day moving average is $6.33 and its two-hundred day moving average is $6.09. The company has a debt-to-equity ratio of 0.27, a current ratio of 4.21 and a quick ratio of 1.76.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded shares of ImmuCell from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday. One equities research analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, the stock currently has an average rating of “Hold”.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Steadtrust LLC purchased a new position in shares of ImmuCell during the 3rd quarter worth $198,000. Mesirow Financial Investment Management Inc. grew its position in shares of ImmuCell by 199.6% in the fourth quarter. Mesirow Financial Investment Management Inc. now owns 36,481 shares of the biotechnology company’s stock valued at $224,000 after purchasing an additional 24,303 shares during the period. Finally, Geode Capital Management LLC lifted its position in ImmuCell by 4.2% during the second quarter. Geode Capital Management LLC now owns 71,852 shares of the biotechnology company’s stock worth $500,000 after buying an additional 2,907 shares during the period. 13.47% of the stock is currently owned by institutional investors and hedge funds.

About ImmuCell

ImmuCell Corporation (NASDAQ: ICCC) is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.

The company’s flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.